Drug Profile
Esketamine - Johnson & Johnson
Alternative Names: Esketamine nasal spray; JNJ-54135419; JNJ-54135419-AAA; JNJ-5419; S-ketamine; SPRAVATOLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder
Most Recent Events
- 08 Oct 2023 Updated safety and efficacy data from a phase III ESCAPE-TRD trial in Major Depressive disorder presented at the 36th European College of Neuropsychopharmacology Congress (ECNP-2023)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Belgium (Sublingual, Film)
- 16 Jun 2023 Janssen-Cilag completes an Expanded Access Program in Major depressive disorder (Treatment-resistant, In adults, In the elderly) in Mexico (Intranasal) (NCT04476446)